Literature DB >> 9023347

Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways.

J L Arbiser1, M A Moses, C A Fernandez, N Ghiso, Y Cao, N Klauber, D Frank, M Brownlee, E Flynn, S Parangi, H R Byers, J Folkman.   

Abstract

The switch from a quiescent tumor to an invasive tumor is accompanied by the acquisition of angiogenic properties. This phenotypic change likely requires a change in the balance of angiogenic stimulators and angiogenic inhibitors. The nature of the angiogenic switch is not known. Here, we show that introduction of activated H-ras into immortalized endothelial cells is capable of activating the angiogenic switch. Angiogenic switching is accompanied by up-regulation of vascular endothelial growth factor and matrix metalloproteinase (MMP) bioactivity and downregulation of tissue inhibitor of MMP. Furthermore, we show that inhibition of phosphatidylinositol-3-kinase leads to partial inhibition of tumor angiogenesis, thus demonstrating that activated H-ras activates tumor angiogenesis through two distinct pathways. Finally, we show evidence for two forms of tumor dormancy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9023347      PMCID: PMC19604          DOI: 10.1073/pnas.94.3.861

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  A link between cyclin A expression and adhesion-dependent cell cycle progression.

Authors:  T M Guadagno; M Ohtsubo; J M Roberts; R K Assoian
Journal:  Science       Date:  1993-12-03       Impact factor: 47.728

2.  Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor.

Authors:  R Yao; G M Cooper
Journal:  Science       Date:  1995-03-31       Impact factor: 47.728

3.  Phosphatidylinositol-3-OH kinase as a direct target of Ras.

Authors:  P Rodriguez-Viciana; P H Warne; R Dhand; B Vanhaesebroeck; I Gout; M J Fry; M D Waterfield; J Downward
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

Review 4.  The family of matrix metalloproteinases.

Authors:  J F Woessner
Journal:  Ann N Y Acad Sci       Date:  1994-09-06       Impact factor: 5.691

5.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

Authors:  B Millauer; S Wizigmann-Voos; H Schnürch; R Martinez; N P Møller; W Risau; A Ullrich
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

6.  Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP).

Authors:  S J Braunhut; M A Moses
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

7.  Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.

Authors:  G Powis; R Bonjouklian; M M Berggren; A Gallegos; R Abraham; C Ashendel; L Zalkow; W F Matter; J Dodge; G Grindey
Journal:  Cancer Res       Date:  1994-05-01       Impact factor: 12.701

8.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

Authors:  K H Plate; G Breier; H A Weich; W Risau
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

9.  Cellular markers that distinguish the phases of hemangioma during infancy and childhood.

Authors:  K Takahashi; J B Mulliken; H P Kozakewich; R A Rogers; J Folkman; R A Ezekowitz
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

10.  The Fps/Fes protein-tyrosine kinase promotes angiogenesis in transgenic mice.

Authors:  P Greer; J Haigh; G Mbamalu; W Khoo; A Bernstein; T Pawson
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

View more
  121 in total

1.  The scl +18/19 stem cell enhancer is not required for hematopoiesis: identification of a 5' bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1.

Authors:  Berthold Göttgens; Cyril Broccardo; Maria-Jose Sanchez; Sophie Deveaux; George Murphy; Joachim R Göthert; Ekaterini Kotsopoulou; Sarah Kinston; Liz Delaney; Sandie Piltz; Linda M Barton; Kathy Knezevic; Wendy N Erber; C Glenn Begley; Jonathan Frampton; Anthony R Green
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

2.  Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma.

Authors:  Francesca Cerimele; Traci Battle; Rebecca Lynch; David A Frank; Emma Murad; Cynthia Cohen; Nada Macaron; John Sixbey; Kenneth Smith; Randolph S Watnick; Aristidis Eliopoulos; Bahig Shehata; Jack L Arbiser
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

3.  Incomplete and transitory decrease of glycolysis: a new paradigm for anti-angiogenic therapy?

Authors:  Sandra Schoors; Anna Rita Cantelmo; Maria Georgiadou; Peter Stapor; Xingwu Wang; Annelies Quaegebeur; Sandra Cauwenberghs; Brian W Wong; Francesco Bifari; Ilaria Decimo; Luc Schoonjans; Katrien De Bock; Mieke Dewerchin; Peter Carmeliet
Journal:  Cell Cycle       Date:  2013-12-13       Impact factor: 4.534

4.  Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model.

Authors:  Amelie M Lutz; Sunitha V Bachawal; Charles W Drescher; Marybeth A Pysz; Jürgen K Willmann; Sanjiv Sam Gambhir
Journal:  Clin Cancer Res       Date:  2014-01-03       Impact factor: 12.531

5.  Reactive oxygen generated by Nox1 triggers the angiogenic switch.

Authors:  Jack L Arbiser; John Petros; Robert Klafter; Baskaran Govindajaran; Elizabeth R McLaughlin; Lawrence F Brown; Cynthia Cohen; Marsha Moses; Susan Kilroy; Rebecca S Arnold; J David Lambeth
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

6.  Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.

Authors:  Khalid Al-Nedawi; Brian Meehan; Robert S Kerbel; Anthony C Allison; Janusz Rak
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

7.  The transcription factor Net regulates the angiogenic switch.

Authors:  Hong Zheng; Christine Wasylyk; Abdelkader Ayadi; Joseph Abecassis; Jack A Schalken; Hermann Rogatsch; Nicolas Wernert; Sauveur-Michel Maira; Marie-Christine Multon; Bohdan Wasylyk
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

8.  Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.

Authors:  Nathalie Magnus; Delphine Garnier; Brian Meehan; Serge McGraw; Tae Hoon Lee; Maxime Caron; Guillaume Bourque; Chloe Milsom; Nada Jabado; Jacquetta Trasler; Rafal Pawlinski; Nigel Mackman; Janusz Rak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

9.  Macrophages Contribute to the Progression of Infantile Hemangioma by Regulating the Proliferation and Differentiation of Hemangioma Stem Cells.

Authors:  Wei Zhang; Gang Chen; Feng-Qin Wang; Jian-Gang Ren; Jun-Yi Zhu; Yu Cai; Ji-Hong Zhao; Jun Jia; Yi-Fang Zhao
Journal:  J Invest Dermatol       Date:  2015-08-19       Impact factor: 8.551

10.  Activated STAT3 is a mediator and biomarker of VEGF endothelial activation.

Authors:  Shao-Hua Chen; Danielle A Murphy; Wiem Lassoued; Gavin Thurston; Michael D Feldman; William M F Lee
Journal:  Cancer Biol Ther       Date:  2008-12-11       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.